RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing


RaNA Therapeutics, a leader in the discovery and development of a new class of medicines that target RNA to selectively activate protein expression within the body’s own cells, today announced the successful completion of a $55 million oversubscribed Series B financing.